January 11, 2018 - By Ellis Scott

The stock of AMBU A/S ORD DENMARK (OTCMKTS:AMBFF) registered a decrease of 8.85% in short interest. AMBFF’s total short interest was 82,400 shares in January as published by FINRA. Its down 8.85% from 90,400 shares, reported previously.

It closed at $89.0782 lastly. It is down 0.00% since January 11, 2017 and is . It has underperformed by 16.70% the S&P500.

Ambu A/S provides healthcare solutions in the fields of anesthesia, patient monitoring and diagnostics, and emergency care in Europe, North America, and internationally. The company has market cap of $. The firm offers anesthesia products, including face masks, resuscitators, and breathing bags; airway management products, such as bronchoscopes, video laryngoscopes, double lumen tubes with integrated camera, endobronchial blockers, laryngeal masks, and resuscitators; and flexible endoscopes comprising bronchoscopes. It has a 445.39 P/E ratio. It also provides neurology products, which include EEG electrodes, EMG electrodes, and EMG guided injections; corkscrew needles, subdermal, electrodes, and probes; and sensors, electrodes, inductance belts, and snoring microphones.

More notable recent AMBU A/S (OTCMKTS:AMBFF) news were published by: which released: “Global Cancer Biomarkers Market 2015-2022 – Research and Markets” on September 21, 2017, also with their article: “Ambrilia Biopharma – The 2011 Biotech Graveyard” published on October 31, 2011, published: “A2 Acquisition Corp. Announces Proposed Qualifying Transaction With Medicenna …” on February 06, 2017. More interesting news about AMBU A/S (OTCMKTS:AMBFF) were released by: and their article: “The Cancer Drugs & Treatments Market – Data, Analysis & Forecasts to 2023′” published on November 21, 2013 as well as‘s news article titled: “Leo Acquisitions Corp. Enters Into Letter of Intent With Axcelon Biopolymers …” with publication date: July 04, 2014.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.